Search Results for "Lovenox"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lovenox. Results 11 to 16 of 16 total matches.
See also: enoxaparin
Drugs for Percutaneous Coronary Interventions
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
, is the anticoagulant most commonly used
during PCI. Enoxaparin (Lovenox), a low molecular
weight heparin (LMWH ...
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an anticoagulant with one or more antiplatelet drugs.
Masoprocol for Multiple Actinic Keratoses
The Medical Letter on Drugs and Therapeutics • Oct 15, 1993 (Issue 907)
Lovenox masoprocol for actinic Keratoses ...
Masoprocol cream 10% (meso-nordihydroguiaretic acid, Actinex - Reed and Carnrick) is now available in the USA for topical treatment of actinic keratoses.
Dalteparin - Another Low-Molecular-Weight Heparin
The Medical Letter on Drugs and Therapeutics • Dec 08, 1995 (Issue 963)
vein thrombosis in high-risk patients after abdominal surgery. Enoxaparin (Lovenox − Rhône-Poulenc ...
Dalteparin (Fragmin - Pharmacia), the second low-molecular-weight heparin to be marketed in the USA, is now available for prevention of deep vein thrombosis in high-risk patients after abdominal surgery. Enoxaparin (Lovenox -Rh ne-Poulenc Rorer) was approved in 1993 for prevention of deep vein thrombosis after hip replacement (Medical Letter, 35:75, 1993) and later approved for use in knee replacement. Five other low-molecular-weight heparins and one heparinoid are under investigation in the USA (MJ Cziraky and SA Spinler, Clin Pharm, 12:892, 1993).
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022 (Issue 1655)
heparins
enoxaparin (Lovenox, and generics) and dalteparin
(Fragmin), which are produced by cleaving UFH ...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Andexxa - An Antidote for Apixaban and Rivaroxaban
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018 (Issue 1549)
)
enoxaparin (Lovenox, and generics) in patients with
active major bleeding. It should also be effective ...
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor Xa
inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto).
Andexanet alfa is the second antidote for a direct oral
anticoagulant to become available in the US, and the
fi rst for factor Xa inhibitors. Idarucizumab (Praxbind)
was approved in 2015 for reversal of the anticoagulant
effect of the direct thrombin inhibitor dabigatran
etexilate (Pradaxa). Andexanet alfa has not...
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014 (Issue 1454)
44.00
Lovenox (Sanofi) STEMI: 30 mg IV bolus plus UA/NSTEMI: 60% neutralized) 66.20
1 mg/kg SC, then 1 ...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.